Inventiva SACA

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

05 May 2025 01:30:00 By Nasdaq GlobeNewswire

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

30 Apr 2025 15:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

30 Apr 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

24 Apr 2025 15:01:28 By Nasdaq GlobeNewswire

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

15 Apr 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

01 Apr 2025 16:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2024 full year results and provides a business update

26 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

19 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

26 Feb 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

20 Feb 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

10 Feb 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

29 Jan 2025 15:00:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 Jan 2025 15:00:00 By Nasdaq GlobeNewswire

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

22 Jan 2025 15:00:00 By Nasdaq GlobeNewswire

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

16 Dec 2024 01:30:00 By Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

12 Dec 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports 2024 Third Quarter Financial Information¹

21 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024  

20 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

20 Nov 2024 15:00:00 By Nasdaq GlobeNewswire